The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease
IJC Heart & Vasculature · 2024-12 · 55 · 101549
DOI: 10.1016/j.ijcha.2024.101549 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJC Heart & Vasculature, 2024-12. Verfasst von Gina Sado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Sweden. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärt-Lungfonden, Vetenskapsrådet, Roche Diagnostics Corporation.
Abstract (Originalsprache)
Background
Atrial fibrillation (AF) screening should be considered in elderly patients with high risk of stroke, which include individuals with hypertension. The biomarker N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can predict incident AF and is increased in hypertensive individuals. The aim of this study is to investigate the incidence of screening-detected AF in elderly individuals in relation to NT-proBNP and hypertension.
Methods
STROKESTOP II is a randomized controlled trial in which 75/76-years-old individuals were invited to a screening study for AF using NT-proBNP as a discriminator of high risk. In this sub-study, a prior hypertension diagnosis was self-reported by participants and measured blood pressure was stratified into hypertension-grades. Individuals with both increased blood pressure (≥140 mmHg) and NT-proBNP ≥ 125 ng/L were defined as a high-risk group. The lowest risk-group was defined as normotensive participants with NT-proBNP 125 ng/l and SBP ≥ 140 mmHg, (AF = 65/1741, 3.7 %) compared to the low-risk group (AF = 2/1444, 0.1 %), p < 0.001.
Conclusion
NT-proBNP is elevated in elderly patients with hypertension and increases with grades of hypertensive disease. NT-proBNP is a strong predictor of AF regardless of high blood pressure, and the risk for screening-detected AF is very low in participants with normal blood pressure and low NT-proBNP. A combination of blood pressure and NT-proBNP could identify suitable participants for AF screening.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Sweden.
- Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden.
- Karolinska Institutet, Department of Clinical Sciences - Danderyd University Hospital, Sweden.
- School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Sweden.
Förderung
- Hjärt-Lungfonden
- Vetenskapsrådet
- Roche Diagnostics Corporation
- Stockholms Läns Landsting
- Center for Innovative Medicine
Zitieren
APA
Sado, G., Kemp Gudmundsdottir, K., Bonander, C., Ekström, M., Engdahl, J., & Svennberg, E. (2024). The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease. IJC Heart & Vasculature, 55, 101549. https://doi.org/10.1016/j.ijcha.2024.101549
Vancouver
Sado G, Kemp Gudmundsdottir K, Bonander C, Ekström M, Engdahl J, Svennberg E. The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease. IJC Heart & Vasculature. 2024;55:101549. doi:10.1016/j.ijcha.2024.101549
BibTeX
@article{Sado2024,
author = {Sado, Gina and Kemp Gudmundsdottir, Katrin and Bonander, Carl and Ekström, Mattias and Engdahl, Johan and Svennberg, Emma},
title = {The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease},
journal = {IJC Heart & Vasculature},
year = {2024},
volume = {55},
pages = {101549},
doi = {10.1016/j.ijcha.2024.101549}
}
EUVIMED